MINNEAPOLIS, June 25, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the recent ...
Current dogma suggests that fluid overload—when associated with acute kidney injury (AKI)—is an independent risk factor for death. Although the volume status of the patient is important, there are ...
Awarded grant supports dedicated pediatric continuous renal replacement therapy (CRRT) device in development for patients between 2.5 and 20 kg where therapeutic options are scarce Company working to ...
Pediatric nephrology and cardiology teams continue to seek out Aquadex for safe, precise fluid management in complex cases MINNEAPOLIS, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), ...
Please provide your email address to receive an email when new articles are posted on . Renal replacement therapy was insufficient for protein delivery in critically ill children with congenital heart ...
(MENAFN- GlobeNewsWire - Nasdaq) The Company has 47 Pediatric Centers utilizing Aquadex MINNEAPOLIS, May 08, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company ...
This trial demonstrates a significant impact of syringe size on fluid administration time in a study setting involving health care provider subjects and a non-clinical pediatric fluid resuscitation ...
MINNEAPOLIS, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardio-renal conditions, addressing the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results